人类肝臟模型市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品（2D 模型、3D 生物列印、肝臟类器官）、按应用（药物发现、学术与研究）、按地区细分，按比赛

2022 年全球人类肝臟模型市场价值为 5.6745 亿美元，预计在预测期内将出现令人印象深刻的增长，到 2028 年CAGR为4.17%。全球人类肝臟模型市场是指创新和先进系统、技术的市场，以及旨在模拟人类肝臟的结构和功能的模型，用于各种应用，特别是在药物开发和毒理学测试中。这些肝臟模型是药物研究中的宝贵工具，使研究人员和组织能够研究肝臟相关疾病、测试新药的安全性和有效性，并减少动物试验的需要。

主要市场驱动因素

药物研究进展

市场概况
预测期	2024-2028
2022 年市场规模	5.6745亿美元
2028 年市场规模	7.2561亿美元
2023-2028 年CAGR	4.17%
成长最快的细分市场	肝臟类器官
最大的市场	北美洲

全球人类肝臟模型市场正在经历需求的变革性激增，这在很大程度上是由药物研究的快速进步所推动的。随着製药业面临越来越大的压力，需要开发更安全、更有效的药物，同时减少时间和成本，人类肝臟模型已成为不可或缺的工具。

道德问题和监管压力

全球人类肝臟模型市场正在经历重大变革，这不仅受到科学进步的推动，而且受到深刻的伦理问题和监管压力的推动。在伦理考量与科学进步日益交织在一起的时代，人类肝臟模型已成为符合不断发展的法规的伦理替代品。

伦理考量已成为科学研究实践的核心。对动物福利和动物测试的道德影响的担忧导致了对研究方法的重新评估。人类肝臟模型提供了一种人道且符合伦理的解决方案，使研究人员无需对动物进行实验即可获得与人类相关的资料。

严重依赖临床前测试的製药业越来越认识到伦理研究实践的重要性。製药公司面临证明其对道德研究和永续发展承诺的压力，而采用人体肝臟模型被视为一种负责任的选择。这种一致性正在推动药物开发中对肝臟模型的需求。

美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等世界各地的监管机构已开始强调伦理研究实践的重要性。这些机构鼓励使用动物试验的替代方案，其中包括人类肝臟模型，以收集与人类反应更相关的资料。

伦理问题延伸到研究中动物试验的减少。人类肝臟模型是这种减少策略的关键部分。它们提供了一种进行临床前测试的方法，而不会出现与动物实验相关的道德两难。监管机构正在积极推动这一转变，推动製药公司探索替代方法。

监管要求不断变化，以适应在临床前测试中使用人体肝臟模型。例如，FDA 已发布指南，强调在药物开发过程早期获取人类特异性资料的重要性。满足这些不断变化的监管要求需要先进的人类肝臟模型。

伦理问题不仅限于科学界，也延伸到公众。消费者越来越意识到他们使用的产品（包括药物）的道德影响。这种意识要求製药公司优先考虑道德研究实践，并考虑动物试验的替代方案。

肝病发生率上升

在令人担忧的全球趋势（肝病发病率不断上升）的推动下，全球人类肝臟模型市场的需求正在激增。随着肝臟相关疾病继续在全球范围内构成重大健康挑战，人类肝臟模型正在成为研究、药物开发和个人化医疗不可或缺的工具。

肝臟疾病，包括肝炎、肝硬化、非酒精性脂肪肝（NAFLD）和肝癌，已成为日益严重的公共卫生问题。不健康的生活方式、酗酒、病毒感染和肥胖等因素导致全球肝病发生率上升。

随着肝病盛行率的增加，迫切需要更有效的疗法和治疗方法。传统的药物开发过程经常面临预测药物如何影响人类肝臟的挑战。人类肝臟模型提供了一个逼真的环境来研究疾病进展和测试潜在的治疗方法，这使得它们在寻求更好的治疗方法中具有无价的价值。

个人化医疗时代正在彻底改变医疗保健。人类肝臟模型使研究人员能够研究个别患者对特定药物的反应。透过在这些模型中使用患者来源的肝组织，可以根据患者独特的基因组成和疾病特征来客製化治疗方法。

肝病在全球造成了巨大的经济和医疗负担。透过增进我们对这些疾病的了解并开发更有效的治疗方法，人类肝臟模型可以有助于降低与肝臟相关疾病相关的社会和经济成本。

人类肝臟模型对于研究肝臟疾病的机制具有不可估量的价值。它们提供了一个在细胞层面上研究疾病进展并识别肝病早期生物标记的平台，从而有可能实现早期诊断和干预。

药物发现和开发是资源密集过程。人体肝臟模型使製药公司能够更有效地筛选潜在的治疗方法，降低后期药物失败的可能性。药物开发流程的简化正在推动製药业对肝臟模型的需求。

技术进步

全球人类肝臟模型市场目前正在经历一场显着的转变，这在很大程度上是由快速技术进步所推动的。这些创新正在彻底改变肝臟研究、药物开发和个人化医疗领域。

3D 生物列印和组织工程的技术进步改变了人类肝臟模型的面貌。研究人员现在可以创造出高度复杂且生理上精确的肝臟组织，与真实的器官非常相似。这项创新显着增强了人类肝臟模型在药物测试和疾病研究中的相关性和可靠性。

器官晶片技术已经成为肝臟建模领域的游戏规则改变者。这些微流体装置复製了肝臟的生理状况，从而能够即时监测和分析肝功能。器官晶片系统的精确度和可扩展性为肝臟研究和药物测试开闢了新途径。

微加工技术使得微型肝臟模型的开发成为可能，并且能够精确控制细胞的布局和结构。这些模型可以对候选药物进行高通量筛选，并为肝病机制提供有价值的见解。

技术的进步使得创建模仿肝臟和体内其他器官之间相互作用的多器官系统成为可能。这些系统可以更全面地了解药物和疾病如何影响整个人体，从而促进更准确地评估候选药物的安全性和有效性。

高解析度显微镜和先进分析工具等尖端成像技术使研究人员能够密切监测和分析肝臟模型的行为。对细胞和分子过程的详细了解增强了我们对肝功能和疾病进展的理解。

人工智慧和机器学习演算法正在整合到肝臟建模中，以分析先进技术产生的大量资料集。这些人工智慧驱动的方法有助于预测药物反应、识别潜在的生物标记并优化实验条件，最终加速研究和开发。

技术进步有助于提高人类肝臟模型的可重复性和可扩展性。这使得研究人员和製药公司更容易进行大规模实验并提高药物筛选过程的效率。

主要市场挑战

肝功能的复杂性

肝臟是一个极其复杂的器官，具有多种功能，包括解毒、新陈代谢和蛋白质合成。在模型中准确复製其所有功能具有挑战性。研究人员正在努力提高肝臟模型的生理相关性，但要实现完整的模拟仍然是一项艰鉅的任务。

长期生存能力

长期维持人类肝臟模型的活力和功能是一项挑战。这些模型中的细胞会随着时间的推移而恶化，影响实验结果的可靠性。研究人员正在探索生物列印和器官晶片技术等策略来解决这个问题。

与其他器官的相互作用

虽然单一肝臟模型提供了有价值的见解，但了解肝臟如何与其他器官相互作用对于综合研究至关重要。开发能够准确复製这些相互作用的多器官系统是研究人员正在积极应对的挑战。

主要市场趋势

多重器官晶片系统

多重器官晶片系统的发展是一个突破性的趋势。这些平台能够研究肝臟和其他器官之间的相互作用，从而更全面地了解药物和疾病如何影响整个人体。这些模型为推动药物开发和个人化医疗带来了巨大的希望。

先进的组织工程和 3D 生物列印

组织工程和 3D 生物列印技术正在迅速发展。这些创新允许创造高度复杂且生理精确的肝臟组织，非常模仿真实的器官。肝臟模型日益复杂，增强了其在药物测试中的相关性和可靠性。

微流体和晶片实验室设备

微流体和晶片实验室设备变得越来越复杂，能够精确控制实验条件。这些平台提供肝功能的即时监测和分析，为药物反应和疾病机制提供有价值的见解。

细分市场洞察

产品洞察

根据产品类别，出于几个令人信服的原因，2D 模型有望保持在全球人类肝臟模型市场的主导地位。首先，它们为研究肝臟相关疾病和药物测试提供了经济有效的解决方案，使其成为研究机构和製药公司的有吸引力的选择。此外，多年来，二维模型已被广泛采用和验证，为持续使用奠定了坚实的基础。它们的简单性和易用性也有助于它们的持久流行。此外，随着细胞培养技术和检测开发的进步不断增强 2D 模型的相关性和准确性，它们可能仍然是肝臟研究的首选。未来几年，肝臟相关研究不断增长的需求以及二维模型的实际优势预计将巩固其在市场上的主导地位。

应用洞察

根据应用，出于几个令人信服的原因，药物发现将继续主导全球人类肝臟模型市场。首先也是最重要的是，製药业对创新和有效疗法的持续追求推动了对可靠的肝臟模型来评估候选药物的持续需求。人体肝臟模型在早期药物测试中发挥着不可替代的作用，使研究人员能够准确评估药物代谢、毒性和疗效。此外，药物标靶的日益复杂性和个人化医疗的推动需要更复杂的肝臟模型，这将药物发现定位为该市场创新的关键驱动力。随着组织工程和生物技术的不断进步，药物发现可能在未来几年保持其主导地位，确保全球人类肝臟模型市场继续蓬勃发展。

区域洞察

预计到 2022 年，北美和欧洲将占据最大的市场份额，这主要归功于这些地区在研发方面不断增加的投资、器官模型的进步以及对创新治疗可能性的接受。此外，肝病发生率的上升，加上主要市场参与者的存在，预计将在预测期内推动市场扩张。此外，由于亚太地区新兴国家的研发投资不断增加，该地区的市场份额也将增加。此外，医疗保健基础设施的持续发展以及公司对创新疗法的高度关注都将促进该地区的成长。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球人类肝臟模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（2D 模型、3D 生物列印、肝臟类器官）
  • 按应用（药物发现、学术与研究）
  • 按地区
  • 按公司划分 (2022)
• 产品市场地图
  • 按产品分类
  • 按应用
  • 按地区

第 6 章：北美人类肝臟模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（2D 模型、3D 生物列印、肝臟类器官）
  • 按应用（药物发现、学术与研究）
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲人类肝臟模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（2D 模型、3D 生物列印、肝臟类器官）
  • 按应用（药物发现、学术与研究）
  • 按国家/地区
• 欧洲：国家分析
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙

第 8 章：亚太地区人类肝臟模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（2D 模型、3D 生物列印、肝臟类器官）
  • 按应用（药物发现、学术与研究）
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国

第 9 章：南美洲人类肝臟模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（2D 模型、3D 生物列印、肝臟类器官）
  • 按应用（药物发现、学术与研究）
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲人类肝臟模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（2D 模型、3D 生物列印、肝臟类器官）
  • 按应用（药物发现、学术与研究）
  • 按国家/地区
• MEA：国家分析
  • 南非人体肝臟模型
  • 沙乌地阿拉伯人体肝臟模型
  • 阿联酋人类肝臟模型
  • 科威特人类肝臟模型

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第14章：竞争格局

• 商业概览
• 产品供应
• 最近的发展
• 财务（据报导）
• 主要人员
• SWOT分析
  • Organovo Holdings Inc
  • BioIVT LLC
  • InSphero AG
  • Emulate Inc
  • Mimetas BV
  • CN Bio
  • Cyfuse Biomedical KK
  • Hurel Corp

第 15 章：策略建议

第 16 章：关于我们与免责声明

Global Human Liver Model Market has valued at USD 567.45 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.17% through 2028. The Global Human Liver Model Market refers to the market for innovative and advanced systems, technologies, and models designed to mimic the structure and functions of the human liver for various applications, particularly in drug development and toxicology testing. These liver models serve as valuable tools in pharmaceutical research, enabling researchers and organizations to study liver-related diseases, test the safety and efficacy of new drugs, and reduce the need for animal testing.

Key Market Drivers

Pharmaceutical Research Advancements

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 567.45 Million
Market Size 2028	USD 725.61 Million
CAGR 2023-2028	4.17%
Fastest Growing Segment	Liver Organoids
Largest Market	North America

The Global Human Liver Model Market is experiencing a transformative surge in demand, driven in large part by the rapid advancements in pharmaceutical research. As the pharmaceutical industry faces increasing pressure to develop safer and more effective drugs while reducing time and costs, human liver models have emerged as indispensable tools.

Pharmaceutical companies are continually searching for more efficient and accurate ways to evaluate drug candidates. Human liver models provide a realistic and dynamic environment to test potential drugs, predict their pharmacokinetics, and assess their toxicity. This level of precision significantly reduces the risk of late-stage clinical trial failures, leading to substantial cost savings and a more streamlined drug development process.

The pharmaceutical landscape is shifting towards personalized medicine, where treatments are tailored to individual patients based on their genetic makeup and unique disease profiles. Human liver models play a pivotal role in this paradigm by allowing researchers to test drug responses on patient-derived liver tissue. Advancements in this area are driving demand for more advanced liver models, leading to innovations and market growth.

Regulatory bodies like the FDA are increasingly emphasizing the need for human-relevant data in drug development and safety assessments. Human liver models, with their ability to mimic human liver functions accurately, are becoming a preferred choice for preclinical studies. As regulatory guidelines evolve to reflect this trend, pharmaceutical companies are investing in these models to ensure compliance and streamline the drug approval process.

Recent global health crises, such as the COVID-19 pandemic, have underscored the urgency of rapid drug development. Human liver models have played a crucial role in studying the impact of viruses on the liver and screening potential treatments. These models enable scientists to expedite research during health emergencies, increasing their importance in the pharmaceutical research landscape.

Ethical concerns and a desire for more humane research practices have led to a push for reduced animal testing. Human liver models provide a viable alternative that allows researchers to obtain human-specific data without harming animals. Pharmaceutical companies are increasingly adopting these models as part of their commitment to ethical research and to meet changing regulatory requirements.

Collaboration between pharmaceutical companies, academic institutions, and technology firms is driving innovation in human liver models. Partnerships leverage collective expertise and resources to develop more advanced and scalable models. These collaborative efforts have the potential to accelerate the growth of the human liver model market.

Ethical Concerns and Regulatory Pressures

The Global Human Liver Model Market is undergoing a significant transformation, driven not only by scientific advancements but also by profound ethical concerns and regulatory pressures. In an era where ethical considerations are increasingly intertwined with scientific progress, human liver models have emerged as ethical alternatives that align with evolving regulations.

Ethical considerations have become central to the practice of scientific research. Concerns about the welfare of animals and the moral implications of animal testing have led to a reevaluation of research methodologies. Human liver models offer a humane and ethical solution, allowing researchers to obtain human-relevant data without subjecting animals to experimentation.

The pharmaceutical industry, which relies heavily on preclinical testing, is increasingly recognizing the importance of ethical research practices. Pharmaceutical companies are under pressure to demonstrate their commitment to ethical research and sustainability, and the adoption of human liver models is viewed as a responsible choice. This alignment is driving demand for liver models in drug development.

Regulatory agencies worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have started to emphasize the importance of ethical research practices. These agencies are encouraging the use of alternatives to animal testing, which includes human liver models, to gather data that is more relevant to human responses.

Ethical concerns extend to the reduction of animal testing in research. Human liver models are a key part of this reduction strategy. They provide a way to conduct preclinical testing without the ethical dilemmas associated with animal experiments. Regulatory bodies are actively promoting this transition, pushing pharmaceutical companies to explore alternative methods.

Regulatory requirements are evolving to accommodate the use of human liver models in preclinical testing. For instance, the FDA has issued guidelines that emphasize the importance of obtaining human-specific data early in the drug development process. Meeting these changing regulatory requirements necessitates the adoption of advanced human liver models.

Ethical concerns are not limited to the scientific community but extend to the general public. Consumers are increasingly conscious of the ethical implications of the products they use, including medications. This awareness has created a demand for pharmaceutical companies to prioritize ethical research practices and consider alternatives to animal testing.

Rising Incidence of Liver Diseases

The Global Human Liver Model Market is witnessing an upsurge in demand, driven by a concerning global trend - the increasing incidence of liver diseases. As liver-related disorders continue to pose significant health challenges worldwide, human liver models are emerging as indispensable tools for research, drug development, and personalized medicine.

Liver diseases, including hepatitis, cirrhosis, non-alcoholic fatty liver disease (NAFLD), and liver cancer, have become a growing public health concern. Factors such as unhealthy lifestyles, alcohol abuse, viral infections, and obesity contribute to the rising incidence of liver diseases globally.

As the prevalence of liver diseases increases, there is an urgent need for more effective therapies and treatments. Traditional drug development processes often face challenges in predicting how drugs will affect the human liver. Human liver models offer a lifelike environment to study disease progression and test potential treatments, making them invaluable in the quest for better therapies.

The era of personalized medicine is revolutionizing healthcare. Human liver models enable researchers to study how individual patients may respond to specific drugs. By using patient-derived liver tissue in these models, treatments can be tailored to the patient's unique genetic makeup and disease characteristics.

Liver diseases impose a significant economic and healthcare burden globally. By advancing our understanding of these diseases and developing more effective treatments, human liver models can contribute to reducing the societal and economic costs associated with liver-related disorders.

Human liver models are invaluable for researching the mechanisms of liver diseases. They provide a platform to study disease progression at the cellular level and identify early biomarkers of liver diseases, potentially enabling earlier diagnosis and intervention.

Drug discovery and development are resource-intensive processes. Human liver models allow pharmaceutical companies to screen potential therapeutics more efficiently, reducing the likelihood of late-stage drug failures. This streamlining of drug development processes is driving demand for liver models in the pharmaceutical industry.

Technological Advancements

The Global Human Liver Model Market is currently undergoing a remarkable transformation, largely fueled by rapid technological advancements. These innovations are revolutionizing the field of liver research, drug development, and personalized medicine.

Technological advancements in 3D bioprinting and tissue engineering have transformed the landscape of human liver models. Researchers can now create highly intricate and physiologically accurate liver tissues that closely resemble the real organ. This innovation has significantly enhanced the relevance and reliability of human liver models in drug testing and disease research.

Organ-on-a-chip technology has emerged as a game-changer in the field of liver modeling. These microfluidic devices replicate the physiological conditions of the liver, enabling real-time monitoring and analysis of liver functions. The precision and scalability of organ-on-a-chip systems have opened up new avenues for liver research and drug testing.

Microfabrication techniques have enabled the development of miniaturized liver models with precise control over cell placement and architecture. These models allow for high-throughput screening of drug candidates and provide valuable insights into liver diseases' mechanisms.

Advances in technology have made it possible to create multi-organ systems that mimic the interactions between the liver and other organs in the body. These systems provide a more holistic understanding of how drugs and diseases affect the entire human body, promoting a more accurate evaluation of drug candidates' safety and efficacy.

Cutting-edge imaging techniques, such as high-resolution microscopy and advanced analytical tools, enable researchers to closely monitor and analyze liver models' behavior. This detailed insight into cellular and molecular processes enhances our understanding of liver function and disease progression.

AI and machine learning algorithms are being integrated into liver modeling to analyze vast datasets generated by advanced technologies. These AI-driven approaches help in predicting drug responses, identifying potential biomarkers, and optimizing experimental conditions, ultimately accelerating research and development.

Technological advancements have contributed to the improved reproducibility and scalability of human liver models. This makes it easier for researchers and pharmaceutical companies to conduct large-scale experiments and increase the efficiency of drug screening processes.

Key Market Challenges

Complexity of Liver Functionality

The liver is an incredibly complex organ with numerous functions, including detoxification, metabolism, and protein synthesis. Replicating all of its functions accurately in a model is challenging. Researchers are working on improving the physiological relevance of liver models, but achieving a complete emulation remains a formidable task.

Long-term Viability

Maintaining the viability and functionality of human liver models over an extended period is a challenge. Cells in these models can deteriorate over time, affecting the reliability of experimental results. Researchers are exploring strategies such as bioprinting and organ-on-a-chip technology to address this issue.

Interactions with Other Organs

While single liver models provide valuable insights, understanding how the liver interacts with other organs is crucial for comprehensive research. Developing multi-organ systems that replicate these interactions accurately is a challenge that researchers are actively addressing.

Key Market Trends

Multi-Organ-on-a-Chip Systems

The development of multi-organ-on-a-chip systems is a groundbreaking trend. These platforms enable the study of interactions between the liver and other organs, providing a more comprehensive understanding of how drugs and diseases affect the entire human body. Such models hold immense promise for advancing drug development and personalized medicine.

Advanced Tissue Engineering and 3D Bioprinting

Tissue engineering and 3D bioprinting technologies are evolving rapidly. These innovations allow for the creation of highly complex and physiologically accurate liver tissues that closely mimic the real organ. The increased sophistication of liver models enhances their relevance and reliability in drug testing.

Microfluidic and Lab-on-a-Chip Devices

Microfluidic and lab-on-a-chip devices are becoming more sophisticated, enabling precise control of experimental conditions. These platforms offer real-time monitoring and analysis of liver functions, providing valuable insights into drug responses and disease mechanisms.

Segmental Insights

Product Insights

Based on the category of Product, 2D Models are poised to maintain their dominance in the Global Human Liver Model Market for several compelling reasons. Firstly, they offer cost-effective and efficient solutions for studying liver-related diseases and drug testing, making them an attractive choice for both research institutions and pharmaceutical companies. Moreover, 2D Models have been widely adopted and validated over the years, establishing a robust foundation for continued use. Their simplicity and ease of use also contribute to their enduring popularity. Furthermore, as advancements in cell culture techniques and assay development continue to enhance the relevance and accuracy of 2D Models, they are likely to remain the go-to choose for liver research. In the coming years, the growing demand for liver-related studies and the practical advantages of 2D Models are expected to cement their dominant position in the market.

Application Insights

Based on Application, Drug discovery is poised to continue dominating the Global Human Liver Model Market for several compelling reasons. First and foremost, the pharmaceutical industry's unceasing quest for innovative and effective therapies drives a constant demand for reliable liver models to assess drug candidates. Human liver models play an irreplaceable role in early-stage drug testing, enabling researchers to evaluate drug metabolism, toxicity, and efficacy accurately. Moreover, the increasing complexity of drug targets and the push towards personalized medicine necessitate more sophisticated liver models, positioning drug discovery as a key driver of innovation in this market. With ongoing advancements in tissue engineering and biotechnology, drug discovery will likely maintain its dominance in the coming years, ensuring that the Global Human Liver Model Market continues to thrive.

Regional Insights

In 2022, it is foreseen that North America and Europe will claim the lion's share of the market, primarily attributable to their growing investments in research and development, advancements in organ models, and the acceptance of innovative therapeutic possibilities in these regions. Additionally, the rising incidence of liver diseases, coupled with the presence of major market players, is expected to propel market expansion during the projected period. Furthermore, the Asia Pacific region is set to increase its market share due to escalating research and development investments in emerging nations within the region. Furthermore, the ongoing development of healthcare infrastructure and a heightened focus by companies on the creation of novel therapeutics are poised to fortify regional growth.

Key Market Players

• Organovo Holdings Inc

• BioIVT LLC

• InSphero AG

• Emulate Inc

• Mimetas BV

• CN Bio

• Cyfuse Biomedical KK

• Hurel Corp

Report Scope:

In this report, the Global Human Liver Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Liver Model Market, By Product:

• 2D Models
• 3D Bio Printing
• Liver Organoids

Human Liver Model Market, By Application:

• Drug Discovery
• Academics & Research

Human Liver Model Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Human Liver Model Market.

Available Customizations:

• Global Human Liver Model market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Liver Model Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 5.2.2. By Application (Drug Discovery, Academics & Research)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Product
  • 5.3.2. By Application
  • 5.3.3. By Region

6. North America Human Liver Model Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 6.2.2. By Application (Drug Discovery, Academics & Research)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Liver Model Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Human Liver Model Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Human Liver Model Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Human Liver Model Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 7.2.2. By Application (Drug Discovery, Academics & Research)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Liver Model Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Human Liver Model Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. France Human Liver Model Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Human Liver Model Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Human Liver Model Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia-Pacific Human Liver Model Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 8.2.2. By Application (Drug Discovery, Academics & Research)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human Liver Model Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. Japan Human Liver Model Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. India Human Liver Model Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. Australia Human Liver Model Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. South Korea Human Liver Model Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. South America Human Liver Model Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 9.2.2. By Application (Drug Discovery, Academics & Research)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human Liver Model Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Human Liver Model Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Human Liver Model Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. Middle East and Africa Human Liver Model Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
  • 10.2.2. By Application (Drug Discovery, Academics & Research)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human Liver Model Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Human Liver Model Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Human Liver Model Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
  • 10.3.4. Kuwait Human Liver Model Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Organovo Holdings Inc
  • 14.6.2. BioIVT LLC
  • 14.6.3. InSphero AG
  • 14.6.4. Emulate Inc
  • 14.6.5. Mimetas BV
  • 14.6.6. CN Bio
  • 14.6.7. Cyfuse Biomedical KK
  • 14.6.8. Hurel Corp

15. Strategic Recommendations

16. About Us & Disclaimer